Eli Casdin

Fluidigm is now Standard BioTools. A company and a name that reflects our commitment to you and your research … To unleash the power of essential, standardized tools that help the life science industry develop breakthrough medicines faster and better. We are evolving to better meet the needs of our customers, bridging a robust and established portfolio of next-generation technologies with an experienced team of leaders dedicated to operational excellence. Standard BioTools – Unleashing reliable tools to accelerate breakthroughs in human health • Providing trusted and repeatable insights that transform scientific discoveries into better outcomes • Improving operating systems through more focused, methodical and consistent processes and an emphasis on quality • Delivering important value to our customers and their research

We see a world where every genetic condition is understood, and every patient receives the care their need to live their fullest life. Our approach to genetic testing, along with having one of the worlds most diverse rare disease data sets, makes us a catalyst for clear, connected and actionable care. Named one of Fast Companys Most Innovative Companies of 2025, were leading the way to a future where we end the diagnostic odyssey. It all begins with a single test.

Effective 11/09/23, EQRx., Inc. is now a wholly-owned subsidiary of Revolution Medicines (https://www.revmed.com/)

The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer. Leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools, the NYGC serves as a nexus for collaboration in genomic research for the New York community and beyond.

Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded in 2016 by leading cardiovascular scientists from the David J. Gladstone Institutes and the University of Texas Southwestern Medical Center. We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease. Our vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of individuals and families fighting this debilitating disease. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease.

At PACT Pharma, our vision is to create potentially curative T cell therapies for solid cancers that are tailored for each and every patient. We are pioneering non-viral, precision-genome engineered, tumor-specific T-cell therapies for cancer patients because we envision a world where everyone has access to personalized treatment regardless of who they are and where they come from. We currently focus on treating solid tumors. PACT Pharma believes that the only way forward is together, and we look for individuals to join our team who share our values. Teamwork and humility are highly prized. So is speaking with kindness. Be ready to share your ideas, because we create a culture that listens to ideas and isn’t afraid to implement them. If you have a passion for turning ideas into realities and seek a work environment where your colleagues are equally engaged and enthusiastic, you’ll want to join us. If you desire a stimulating fast-paced environment, working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team. We are a rapidly expanding, innovative, and collaborative workforce working towards one main goal, eradicating cancer! We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients. Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com. Follow Magenta on Twitter: @magentatx.

Prominex was founded by individuals passionate about transforming molecular testing in non-traditional testing settings. Together, we are focused on developing near-patient diagnostics with rapid, low-cost, PCR level performance to enable broad accessibility to clinically actionable testing around the globe. Our Prominex System is a transformative molecular diagnostic testing solution for near patient care settings designed to deliver results in 5 minutes. Our novel dCliP molecular technology is the foundational chemistry enabling fast, accurate, easy-to-use, multiplexed, and low-cost molecular diagnostic assays providing unprecedented value to practitioners.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Community Guidelines: https://bit.ly/3t2xeR9

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

Invitae is a leader in medical-grade genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world's medical-grade genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the exploding medical genetics industry by harnessing the power of advanced technologies – robotics, artificial intelligence, machine learning, software engineering – and world-class genetic expertise. We provide genetic information that guides decisions for patients facing a vast array of health questions, from ultra-rare diseases and the most common cancers to starting a family. The team driving our mission thrives in a culture designed to enable innovation at scale. We are grounded in freedom with responsibility and a universal sense of urgency and ownership. Employees are empowered to speak up, try new things and make decisions that push us forward. We provide all employees with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. Each day at Invitae means driving forward toward a new era in which everyone can have their health decisions guided by genetics.

Fluidigm is now Standard BioTools. A company and a name that reflects our commitment to you and your research … To unleash the power of essential, standardized tools that help the life science industry develop breakthrough medicines faster and better. We are evolving to better meet the needs of our customers, bridging a robust and established portfolio of next-generation technologies with an experienced team of leaders dedicated to operational excellence. Standard BioTools – Unleashing reliable tools to accelerate breakthroughs in human health • Providing trusted and repeatable insights that transform scientific discoveries into better outcomes • Improving operating systems through more focused, methodical and consistent processes and an emphasis on quality • Delivering important value to our customers and their research

At Rockefeller University, bioscience is what we do. It’s all we do. Our exclusive focus is on uncovering the processes that underlie life. How cells work. How genes are controlled. What makes us sick, and what keeps us healthy. The research underway in our labs today is leading to the breakthroughs that will transform medicine tomorrow. A place of both quiet contemplation and intense scientific energy, our unique campus is the backdrop to a culture that values both independence and collaboration. Each of our 82 laboratories is led by a Rockefeller scientist who reports directly to the president. We have 9 broad areas of research, but 0 formal departments and a lean administration with minimal bureaucracy. Our scientists have won a collective 25 Nobel Prizes, and 5 Nobel Prize winners are currently on our faculty. 41 percent of our faculty have been elected to the prestigious National Academy of Sciences. We are a modern, thriving institution: Over the past 10 years we have invested over $2 billion in new facilities, scientific equipment, faculty recruitment, and research support. Our graduate program attracts exceptional Ph.D. students from around the world. They pay $0 in tuition.

SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention, and treatment of disease through the next generation of proteomics.

We see a world where every genetic condition is understood, and every patient receives the care their need to live their fullest life. Our approach to genetic testing, along with having one of the worlds most diverse rare disease data sets, makes us a catalyst for clear, connected and actionable care. Named one of Fast Companys Most Innovative Companies of 2025, were leading the way to a future where we end the diagnostic odyssey. It all begins with a single test.

Effective 11/09/23, EQRx., Inc. is now a wholly-owned subsidiary of Revolution Medicines (https://www.revmed.com/)